LATE-BREAKING ABSTRACT (LBA) SUBMISSION GUIDELINES

LBA Abstract Submission Site Opens: April 26, 2021
LBA Abstract Submission Site Closes: June 7, 2021 at 11:59 PM EST

AUA’s late-breaking abstract policy allows the submission of late-breaking abstracts only for trials for which no preliminary data are available at the time of the standard abstract submission deadline (March 1, 2021).

Late-breaking submission is not a mechanism to submit updated data when preliminary data are available by the standard abstract submission deadline, nor to provide an opportunity to revise and resubmit abstracts rejected during the standard submission period.

Case Reports are not accepted.

Trials in Progress are eligible for consideration only if there are preliminary results.

Work that has been previously presented or published elsewhere (as an abstract or a manuscript) prior to the AUA Annual Meeting is not eligible for submission as a late-breaking abstract.

Late-breaking abstracts are intended to allow for the timely presentation of late-breaking news of interest to Annual Meeting attendees. Submissions are prioritized in the following order:

• Results of phase III clinical trials
• Results of phase II clinical trials
• Interim analyses of phase III trials that describe important secondary end-points
• Prospective multi-institution clinical trials

The authors must fully describe all funding sources for their investigation.

• Completion of an abstract submission affirms that all listed abstract authors have agreed to its submission for presentation at the American Urological Association, Inc. (AUA) Annual Meeting and publication of the abstract in the August Abstract Supplement to The Journal of Urology®.

• The submitting author must take care to review the abstract to ensure there are no errors in spelling or grammar, missing author names, etc., prior to the submission deadline as no revisions/corrections can occur after the submission site closes.
• To submit your abstract, you will be required to complete a non-exclusive license agreement, as the AUA may capture accepted abstract presentations and use as deemed appropriate for educational purposes.

• Submission of an abstract constitutes the author's commitment to present the abstract as accepted. The author/presenter is responsible for any expenses associated with the preparation, submission and presentation of an abstract.

• All completed abstract submissions are peer-reviewed and graded individually based on scientific merit and originality. All abstract submissions must be written in English and all accepted abstract presentations must be presented in English.

Preparation of Abstracts

1. Size: The size of the abstract is limited to 2,280 characters not including spaces. This includes title, body of abstract, tables and graphics.
   - Tables = 225 characters per table
   - Graphics = 225 characters per graphic

2. Title: The title should clearly define the topic and contain no abbreviations. For professional consistency, titles should not be bolded, underlined, italicized or written in all caps or all lowercase letters. The AUA will ensure the abstracts/titles are properly formatted for the various publications in The Journal of Urology®, the AUA Annual Meeting website, etc.
   - DO: How to Type a Winning Title for an AUA2021 Abstract
   - DON'T: HOW TO TYPE A WINNING TITLE FOR AN AUA2021 ABSTRACT
     How to Type a Winning Title for an AUA2021 Abstract
     how to type a winning title for an aua2021 abstract
     How to Type a Winning Title for an AUA2021 Abstract

3. Authors: Spell out the names of all authors using full first name and last name. Middle initials may be included. Please do not include medical credentials in the name fields of the abstract. Please maintain consistency in authors' names on multiple abstracts.

4. Presenting Author: The presenting author cannot be an employee of, or have a financial relationship with, the commercial interest that controls the content of the study/presentation. Principal Investigators responsible for research and development are permitted to present as long as they resolve their COI and they are not employees of the commercial interest.

   In all printed publications, an asterisk (*) denotes the presenting author.
5. **Body of Abstract:** The abstract should be informative and detailed.

- The body must contain four separate paragraphs:
  a) Introduction and Objective
  b) Methods
  c) Results
  d) Conclusions
- Inclusion of specific outcomes data is necessary for all abstracts; this applies to Trials in Progress as well – which must supply at least preliminary results to be eligible for consideration. The AUA will reject abstracts with no listed results or abstracts with a statement that reads, “Results will be discussed”.

- Indicate the major new findings of the study.

- Standard abbreviations: During its first use, the full term should be written out, followed with the abbreviation in parentheses. Thereafter, the standard abbreviation may be used.

- It is not permissible to use proprietary names of drugs; generic names must be used whenever available.

6. **Source of Funding:** This is a required field in the submission form and must be completed. You must indicate grant support on the "Source of Funding" page. If there is no support to note, please list "None".

**Please note: Abstracts deemed purely for marketing purposes will not be accepted.**

7. **Conflict of Interest and Disclosure Statement:** All authors must disclose any conflicts of interest. The electronic submission process will not allow for the submission of abstracts without this information completed for each author listed on the abstract. Please make sure you are aware of the disclosures of all of the abstract’s authors before beginning your abstract submission process.

8. **Category List:** Authors must select a single category from the list provided.

9. **Keywords:** Authors must select up to 3 keyword entries from the provided Keyword Index that best describes the subject of the abstract.